Key terms

About ANTX

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANTX news

Apr 08 3:55am ET Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties by TipRanks Apr 02 4:35am ET AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities by TipRanks Apr 02 12:35am ET Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects by TipRanks Mar 31 2:02am ET AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties by TipRanks Mar 28 4:12pm ET AN2 Therapeutics reports Q4 EPS (57c), consensus (75c) by TipRanks Mar 05 10:25am ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Mar 05 4:55am ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Mar 01 12:19pm ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Feb 28 4:35pm ET SHAREHOLDER ALERT: Potential Recovery for AN2 Therapeutics, Inc. (ANTX) Investors by TipRanks Feb 12 7:14pm ET AN2 Therapeutics downgraded to Market Perform from Outperform at Leerink by TipRanks Feb 12 11:44am ET AN2 Therapeutics downgraded to In Line from Outperform at Evercore ISI by TipRanks Feb 12 10:54am ET AN2 Therapeutics downgraded to Perform from Outperform at Oppenheimer by TipRanks Feb 12 10:50am ET AN2 Therapeutics downgraded to Market Perform from Outperform at JMP Securities by TipRanks Feb 12 9:55am ET AN2 Therapeutics, Inc. (ANTX) was downgraded to a Hold Rating at JMP Securities by TipRanks Feb 12 8:25am ET AN2 Therapeutics Reassesses Phase 3 Trial Amid Efficacy Concerns by TipRanks Feb 12 8:12am ET AN2 Therapeutics Reviews Epetraborole Phase 3 Trial Enrollment by TipRanks Feb 12 8:09am ET AN2 Therapeutics Reviews Phase 2 Data, Pauses Phase 3 Trial Enrollment by TipRanks Feb 12 6:47am ET AN2 Therapeutics pausing enrollment in Phase 2 trial of epetraborole by TipRanks

No recent press releases are available for ANTX

ANTX Financials

1-year income & revenue

Key terms

ANTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Student demonstrators occupy the pro-Palestinian "Gaza Solidarity Encampment" on the West Lawn of Columbia University on April 24, 2024 in New York City.
Michael M. Santiago/Getty Images
What the pro-Palestinian protesters on college campuses actually want
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stagflation fears just hit Wall Street. Now for the next crucial report on prices
Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges 15% on ‘aggressive’ AI spending plans
GettyImages-1159438448 copy.jpg
Lyndon Stratford/iStockphoto/Getty Images
Americans are falling behind on their payments